Advertisement
The Scientist
The Scientist

Triple therapy safety

NEW YORK, July 18 (Praxis Press) Multidrug antiretroviral therapy has decreased the morbidity and mortality associated with human immunodeficiency virus (HIV) infection, but the long-term effects and safety of this treatment are unknown. Gulick and colleagues studied the durability and toxicity associated with combined indinavir, zidovudine and lamivudine therapy in HIV-infected patients (see paper). Almost 65% of patients continued therapy for three years. Serum viral loads remained suppressed

July 21, 2000

NEW YORK, July 18 (Praxis Press) Multidrug antiretroviral therapy has decreased the morbidity and mortality associated with human immunodeficiency virus (HIV) infection, but the long-term effects and safety of this treatment are unknown. Gulick and colleagues studied the durability and toxicity associated with combined indinavir, zidovudine and lamivudine therapy in HIV-infected patients (see paper). Almost 65% of patients continued therapy for three years. Serum viral loads remained suppressed and CD4 counts remained elevated relative to baseline values. The main adverse effect was nephrolithiasis. Multidrug antiretroviral therapy can achieve prolonged suppression of HIV viremia.

Advertisement

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement
NeuroScientistNews
NeuroScientistNews

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
The Scientist
The Scientist
Advertisement
NeuroScientistNews
NeuroScientistNews
Life Technologies